Nevro Spinal Cord Stimulators

Individual product liability actions are proceeding against Nevro Corp. and parent Globus Medical over Senza, Senza II, Senza Omnia, and HFX spinal cord stimulation systems, with at least one case, Yusnukis v. Nevro Corp., No. 1:24-cv-00355 (D.N.M.), surviving a preemption challenge in February 2026. Plaintiffs allege manufacturing defects, failure to warn, and fraudulent misrepresentation regarding device performance, with claims that permanent implants malfunctioned or deviated from FDA-approved specifications after trial systems performed differently.

Nevro spinal cord stimulator product liability litigation remains in pre-MDL posture. A centralization petition identifying 17 cases across six jurisdictions was filed with the JPML on or about June 26, 2026, seeking assignment to the Central District of California alongside MDL-3181 (Boston Scientific). No hearing date has been set. The JPML declined to create a single industry-wide spinal cord stimulator MDL in its June 5, 2026 transfer order.

Nevro reports 80,000+ patients globally treated with 10 kHz Therapy as of 2022. No MDL established as of August 2026. Device systems: HFX iQ, Senza, Senza II, Senza Omnia. Reported injuries include permanent neuropathy, paralysis, syncope, incontinence, device malfunction, loss of pain relief, and autonomic complications. Active litigation in Louisiana and New Mexico federal courts with parallel federal claims surviving initial preemption challenges.

• Louisiana

  Active litigation in M.D. Louisiana: Greene v. Nevro Corp., No. 3:23-cv-01648-JWD-RLB (Judge John W. deGravelles). Plaintiff alleges permanent nerve damage, loss of ambulation following Senza SCS implantation December 2022. Court granted motion to dismiss with leave to amend January 31, 2025; 28-day amendment window. Parallel federal claims survive preemption challenge.

• New Mexico

  Active litigation in D. New Mexico: Yusnukis v. Nevro Corp., No. 1:24-cv-00355. Plaintiff alleges syncopal episodes, incontinence, device explantation after 49 days. Claims include manufacturing defect, failure to warn, fraud, and N.M. Unfair Practices Act violations. Nevro preemption motion pending resolution February 2026.

• Costa Rica (Manufacturing)

  FDA-approved manufacturing facility in Coyol Free Trade Zone, Alajuela, operational since October 2022. Produces HFX platform, Senza, and Omnia SCS systems for global distribution. Facility implicated in deviation-from-specification allegations in pending U.S. litigation.

• California (Corporate)

  Nevro Corp. headquartered Redwood City. Corporate defendant in nationwide litigation. HFX iQ, Senza Omnia systems designed and marketed from California operations.

Nevro SCS claims depend on state product-liability statutes, implant/explant dates, symptom onset, discovery of device causation, and tolling agreements. The JPML petition specifically flags a tolling agreement through August 1, 2026 for movants’ counsel, but that may not protect every claimant.